Articles from Evident Vascular, Inc.

Evident Vascular, Inc., today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Evident Vascular® Guidance System and Evident® peripheral imaging catheters. The Evident Vascular Guidance System is intended for ultrasound examination of intravascular pathology during peripheral vascular interventions.

Evident Vascular, Inc., a medical technology company developing a best-in-class intravascular ultrasound (IVUS) platform powered by artificial intelligence, today announced the successful closing of its Series B financing with new investors Shangbay Capital and two undisclosed multinational strategics joining founding investor Vensana Capital. The funding will accelerate the development of the Company’s advanced IVUS technology designed to enhance vascular imaging and patient outcomes and support 510(k) FDA clearance ahead of U.S. market launch.

Evident Vascular, Inc., a medical technology startup backed by Vensana Capital® developing an AI-powered next-generation intravascular ultrasound (IVUS) platform, is pleased to announce the appointment of Scott R. Ward to its Board of Directors.

Evident Vascular, Inc. a medical technology startup developing a next-generation intravascular ultrasound (IVUS) platform leveraging artificial intelligence to enable superior imaging and streamlined workflows, announced today its Scientific Advisory Board and expansion of its Board of Directors.

Evident Vascular, Inc., a medical technology startup developing a next-generation intravascular ultrasound (IVUS) platform leveraging artificial intelligence to enable superior imaging and streamlined workflows, announced today that it has launched with a $35 million Series A financing from Vensana Capital®.